• Даминов Б.Т., Абдувахитова А.Н.
  Ташкентский педиатрический медицинский институт, Республика Узбекистан, г. Ташкент

Аннотация

Обзор посвящён изучению особенностей гематологического статуса, характеристики специфического и неспецифического иммунитета у больных хроническим гломерулонефритом (ХГН) и их динамику на фоне базисной терапии с дальнейшем включением нового перорального антикоагулянта-ривароксабан. Заключение: Применяемая терапия оказывала положительное влияние на иммуногематологические сдвиги у больных ХГН. Применение антикоагулянта способствовало достижению меньшей концентрации реактивных и антитела продуцирующих лимфоцитов, CD4+ и CD 95+ клеток, показателя гранулярности нейтрофилов.

Калит сузлар

хронический гломерулонефрит, иммунология, циркулирующие иммунные комплексы, ривароксабан.

Адабиёт

Keren Borensztajn 1, Maikel P Peppelenbosch, C Arnold Spek. Coagulation Factor Xa Signaling: The Link Between Coagulation and Inflammatory Bowel Disease?// Trends Pharmacol Sci. 2009 Jan;30(1):8-16

Hoess A, Watson S, Siber GR, Liddington R. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5Å resolution. EMBO J. 1993;12:3351–3356.

Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–430.

Redecha P, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110:2423–2431.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2

Barbour S.J., Greenwald A., Djurdjev O. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81:190–195.

Fenton A., Smith S.W., Hewins P. Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC Nephrol. 2018;19:207.

Harza M., Ismail G., Mitroi G. Histological diagnosis and risk of renal vein thrombosis, and other thrombotic complications in primitive nephrotic syndrome. Rom J Morphol Embryol. 2013;54:555–560.

Li S.-J., Guo J.-Z., Zuo K. Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome–a prospective study. Thromb Res. 2012;130:501–505.

Li S.J., Tu Y.M., Zhou C.S. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol. 2016;20:212–217.

Gyamlani G., Molnar M.Z., Lu J.L. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32:157–164.

Kelddal S., Nykjær K.M., Gregersen J.W., Birn H. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol. 2019;20:139.

Medjeral-Thomas N., Ziaj S., Condon M. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol. 2014;9:478–483.

 Apostolakis S., Lane D.A., Guo Y. Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2013;61:386–387.

Roldan V., Marin F., Fernandez H. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143:179–184.